Pharma: Page 3

  • Packaging for a pediatric formulation of Pfizer and BioNTech's COVID-19 vaccine
    Image attribution tooltip
    Courtesy of Pfizer

    Pfizer says 3 doses of its COVID-19 vaccine works in youngest children

    The drugmaker, along with partner BioNTech, plans to submit the new data to the FDA this week. The agency has scheduled a meeting for outside experts to review the data in mid-June.

    By May 23, 2022
  • Image attribution tooltip
    Westend61 via Getty Images
    Sponsored by GoodRx

    Common barriers to patient engagement: What's your strategy?

    As with treatment, and even adherence, there is no 'one size fits all' when it comes to patient engagement.

    May 23, 2022
  • Trendline

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • Image attribution tooltip
    Bayer AG

    Bayer backs out of Atara cell therapy deal

    The German drugmaker will hand back rights to two CAR-T cell therapies it was developing with Atara, which said it would reassess its strategy for the programs.

    By May 20, 2022
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip

    AbbVie asks FDA to approve Parkinson's treatment

    The company believes the treatment, which uses prodrug versions of two commonly used Parkinson's medications, could be a longer-lasting option for patients and blockbuster product for AbbVie.

    By May 20, 2022
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers' Opdivo comes up short in bladder cancer trial

    The top-selling immunotherapy failed to improve survival in first-line urothelial carcinoma, a tumor type that's proved difficult to treat with drugs like Opdivo.

    By May 16, 2022
  • Image attribution tooltip
    Permission granted by Vetter Pharma
    Sponsored by Vetter Pharma

    Making sub-visible particles visible

    Sub-visible particles can lower the effectiveness of a drug, which is why regulatory authorities are demanding processes be developed, validated and set up in such a way as to minimize all forms of contamination. 

    By Dr. Melanie Zerulla-Wernitz, Head of the Analytical Science Laboratory, Vetter Pharma • May 16, 2022
  • Lilly wins FDA approval for new kind of diabetes drug

    Tirzepatide, now branded as Mounjaro, helped improve blood sugar control in testing and has been shown to have powerful weight loss effects as well, making it one of the most closely watched drugs in Lilly's pipeline.

    By Updated May 16, 2022
  • Image attribution tooltip
    Jacob Bell / BioPharma Dive

    FDA approves oral version of Mitsubishi's ALS drug

    Called Radicava ORS, this version is taken by mouth rather than via an hourlong infusion, which may help improve the drug's convenience and use.

    By May 13, 2022
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Key Bristol Myers drug holds up in long-term psoriasis study

    Deucravacitnib, forecast by Bristol Myers to hit $4 billion in peak sales, is under FDA review with an approval decision due by September. The agency's view of its safety will be key to its future.

    By May 12, 2022
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers acquires BridgeBio drug aimed at emerging cancer target

    The pharma will pay $90 million to license BridgeBio's experimental candidate, joining a lengthening list of large drugmakers aiming to treat cancer by blocking a protein called SHP2.

    By May 12, 2022
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images

    Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

    A treatment combination involving Roche's anti-TIGIT medicine tiragolumab missed its goal in a Phase 3 lung cancer study that was viewed as a proof point for the drug class.

    By May 11, 2022
  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs

    The deal, which hands Pfizer full rights to the biotech's fast-selling Nurtec ODT, could provide a much needed spark for the sector after months of stock market declines. 

    By , Updated May 10, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J ends hepatitis B, HPV vaccine work with Bavarian Nordic

    The companies' hepatitis B program never reached clinical testing, while J&J said it would no longer develop an HPV vaccine because of the "widespread uptake" of effective shots from other companies.

    By May 9, 2022
  • Image attribution tooltip

    Novartis suspends production of two radiopharmaceutical drugs over quality concerns

    Due to potential issues in manufacturing, the pharma is halting deliveries of two cancer drugs, Lutathera and Pluvicto, in the U.S. and Canada, a setback for a business in which the company has invested heavily.  

    By May 6, 2022
  • Image attribution tooltip

    Sponsored by Acceleration Point

    Digital key opinion leaders: who are they?

    As scientific discussions increase online, Medical Affairs teams need ways to listen to conversations.  

    May 2, 2022
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers wins FDA approval for first drug to treat inherited heart condition

    Bristol Myers paid $13 billion to acquire the drug's maker, MyoKardia, and expects it to become a blockbuster. But a tricky dosing regimen, as well as safety concerns, could challenge the pharmaceutical giant's lofty forecast. 

    By April 28, 2022
  • Lilly's closely watched diabetes drug scores in obesity trial

    Called tirzepatide, the drug significantly lowered weight loss in a large study, findings that add to growing evidence that a class of medicines originally meant for diabetes may effectively treat obesity.

    By April 28, 2022
  • Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.

    FDA sets back Novartis' best chance at a COVID-19 drug

    The agency indicated another trial of the drug, developed by Molecular Partners, will be needed. But whether such a study is doable is yet to be determined, according to Novartis' CEO Vas Narasimhan.

    By Kristin Jensen • April 27, 2022
  • Image attribution tooltip

    Novartis names longtime analyst as top dealmaker amid organizational shakeup

    Novartis said in an earnings presentation Tuesday that it hired biotech analyst Ronny Gal as chief strategy and growth officer and revealed more details about planned layoffs as the company restructures.

    By April 26, 2022
  • Nektar begins sweeping layoffs after $2B Bristol Myers deal falls apart

    Loss of the lucrative partnership has triggered a wide-ranging restructuring that will pare down Nektar’s workforce by about 70%.

    By April 26, 2022
  • Image attribution tooltip
    Courtesy of Roche

    Roche stumbles in latest setback for an emerging group of breast cancer drugs

    The Phase 2 failure marks the second negative result in two months for a closely watched group of medicines, known as SERDs, that are being developed by several large pharmaceutical companies.

    By April 25, 2022
  • Image attribution tooltip

    Sponsored by Medscape

    Connect to the conversation: Pediatric mental health

    More children than ever are experiencing mental health issues, so what can parents and loved ones do to help address these issues and prevent them before they start?

    April 25, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Drug price hikes moderate as rebates rise, report finds

    List prices for branded medicines rose by nearly 5% last year, according to IQVIA, a figure that fell to 1% after accounting for rebates and discounts.

    By April 21, 2022
  • AbbVie ends research alliance on BioArctic Parkinson's drug

    The company's decision is a blow to Sweden-based BioArctic, which two months ago was expecting AbbVie to advance the drug into Phase 2 this year.

    By April 20, 2022
  • A Merck & Co. sign sits in front of a Georgia facility July 9, 2002 in Duluth, Georgia.
    Image attribution tooltip
    Erik S. Lesser via Getty Images

    Merck brings former executive back to lead ex-US pharmaceuticals business

    Joseph Romanelli is returning from a short stint at the Chinese drugmaker Ji Xing Pharmaceuticals. In his new role at Merck, he will oversee more than 75 markets outside the U.S. and about 14,000 employees.

    By Kristin Jensen • April 20, 2022